A

Asimov

Genetic design software with engineered cells

Principal Scientist - Lentiviral Vector Cell Line Development

Bioprocess & BiomanufacturingConfirmed live in the last 24 hours
Full-timeBoston, MA, USA$170k - $190k /yrIn-person

About the Job

Requirements

  • A Master of Science or PhD in Biological Engineering, Virology, Cell Biology, Molecular Biology, or a related field is required.
  • At least 10 years of hands-on experience in biopharma is required, including at least 6 years focused on lentiviral vector producer or packaging cell line development supporting GLP or GMP production of cell or gene therapies.
  • At least 2 years of experience managing direct reports and providing technical guidance is required.
  • Experience communicating technical work to external stakeholders and translating their needs into technical plans is required.
  • Publications, patents, and/or conference presentations demonstrating external communication of scientific work are required.
  • Strong written and verbal communication skills are required.

Responsibilities

  • Set and steer the scientific roadmap for the Lentiviral Vector cell line development platform.
  • Perform lentiviral vector stable producer cell line development processes, including transfection, pool generation, single-cell cloning, clone screening and characterization, and cell banking using state-of-the-art equipment.
  • Serve as the primary Lentiviral Vector cell line development technical contact on customer and commercial projects; partner with the commercial team to present platform capabilities to prospective partners and translate customer requirements into executable project plans.
  • Provide technical leadership and mentorship to team scientists, including managing direct reports and setting standards for experimental design, data analysis, and record-keeping.
  • Represent Lentiviral Vector cell line development on cross-functional and leadership-facing project teams, making decisions on development strategy and communicating progress, risk, and plans.
  • Develop novel workflows and applications to support innovation.
  • Support research projects developing viral vector production methods to enhance product quality attributes such as empty/full ratio, potency, and cell targeting.
  • Work cross-functionally to support the Lentiviral Vector cell line development platform and collaborate with Synthetic Biology and Process Development teams.
  • Design experiments, analyze data, troubleshoot, and maintain detailed records.
  • Represent the company's science externally through publications and presentations at industry conferences.

Desired Qualifications

  • Experience with downstream purification and PQ assessment of lentiviral vectors, T-cell transduction assays, viral genome engineering, and/or host cell genome engineering related to virus production or producer cell line technologies is highly desired.
  • Experience with process development at Ambr or benchtop bioreactor scale is a plus.
  • Ability to work with large, multidimensional datasets and apply statistical or computational methods to derive biological or process insights is desired.

About the Company

Asimov

Genetic design software with engineered cells

What Asimov does: It provides an integrated synthetic biology platform for biopharma, combining cloud-based software for designing, simulating, and optimizing genetic systems with engineered GMP host cells used for therapeutic production. How its products work: The software lets users design and run simulations of genetic circuits and optimize production processes, while engineered cell lines are used to express proteins or produce viral vectors; services include process development and stability studies. How it differs from competitors: It bundles an end-to-end suite—genetic design software, in-house cell-line development, and process development—along with a performance guarantee, such as a 4 g/L monoclonal antibody titer promise, reducing client risk. What its goal is: To help biopharma customers achieve high yields and scalable production of biologics, gene therapies, and programmable medicines through a tightly integrated platform.

Company size
51-200
Company stage
Series B
Total funding
$204.7M
Headquarters
Boston, MA
Founded
2017

Recently Posted Jobs

Explore more opportunities at Asimov

See more jobs